Cravath, Swaine & Moore has taken the lead for Mylan on its deal for Meda, along with leading Swedish firm Vinge and top Dutch shop NautaDutilh. Cravath previously advised Mylan in 2007 on its $6.6 billion acquisition of Merck KGaA’s worldwide generic drug business.
Mylan only recently gave up on a deal with Perrigo, abandoning a $27 billion hostile bid for its former target in November. Back in August, Mylan agreed to dismiss a conflicts of interest suit it filed against onetime counsel Kirkland & Ellis, which had initially represented Teva in its failed $40 billion takeover attempt of Mylan. (Wilson Sonsini Goodrich & Rosati represented Mylan on that matter, while Gibson, Dunn & Crutcher took the lead for Kirkland.)
